Session V: Presentation of Selected Non-Colorectal Cancer Abstracts – Biliary Tract and Pancreatic Cancer

Chair(s)

• 

  Andrzej Deptala

  Medical University of Warsaw
  Warsaw, Poland
• 

  Gerald Prager, MD

  Medizinische Universität Wien
  Vienna, Austria

Presentations:

• 08:00 – 08:08 CEST

  SO-1: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
  

  Abstract Presenter: James Harding
• 08:08 – 08:16 CEST

  SO-2: Quantitative Risk-benefit Assessment of Ivosidenib Compared to Placebo in Patients with IDH1-mutated Intrahepatic Cholangiocarcinoma: Phase 3 ClarIDHy trial
  

  Abstract Presenter: Maeve Lowery
• 08:16 – 08:24 CEST

  SO-3: Clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer: preliminary results from the multicenter B-REAL study
  

  Abstract Presenter: Monica Niger
• 08:24 – 08:32 CEST

  SO-4: Impact of molecular profiling on survival in patients with advanced biliary tract cancers
  

  Abstract Presenter: Leony Antoun
• 08:32 – 08:40 CEST

  SO-5: Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study
  

  Abstract Presenter: Antoine Hollebecque
• 08:40 – 08:50 CEST

  Discussant: SO-2, SO-3, SO-4, SO-5
  

  Discussant: Teresa Macarulla, MD, PhD – Vall d’Hebrón University Hospital
• 08:50 – 09:00 CEST

  LBA-1: The Phase III study: Targeted Intra-Arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with Sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC)
  

  Abstract Presenter: Michael J. Pishvaian, MD, PhD – Johns Hopkins University
• 09:00 – 09:08 CEST

  SO-6: Changes in the Course of Advanced Pancreatic Cancer Treatment With Systemic Chemotherapy: A Pooled Analyses of Five Clinical Trials From Two Decades of Clinical Research Within the German AIO Study-Group
  

  Abstract Presenter: Lena Weiss
• 09:08 – 09:16 CEST

  SO-7: First-line liposomal irinotecan (nal-IRI), oxaliplatin and S-1 (NASOX) in unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase I/II study
  

  Abstract Presenter: Changhoon Yoo
• 09:16 – 09:24 CEST

  SO-8: Predictive Values of Blood-Based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer
  

  Abstract Presenter: Jean-Baptiste Bachet
• 09:24 – 09:35 CEST

  Discussant: LBA-1, SO-6, SO-7, SO-8
  

  Discussant: Gerald Prager, MD – Medizinische Universität Wien